ArticleAntimicrobial agents and chemotherapy2007
Azithromycin blocks quorum sensing and alginate polymer formation and increases the sensitivity to serum and stationary-growth-phase killing of Pseudomonas aeruginosa and attenuates chronic P. aeruginosa lung infection in Cftr(-/-) mice.
Article in Antimicrobial agents and chemotherapy, 2007. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 116 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
116 citing papers in PubMed, 257 citations in OpenAlex.
- Impact of azithromycin on the clinical and antimicrobial effectiveness of tobramycin in the treatment of cystic fibrosis.Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society · 2017Trial
- Azithromycin to prevent Pseudomonas aeruginosa ventilator-associated pneumonia by inhibition of quorum sensing: a randomized controlled trial.Intensive care medicine · 2012Trial
- Azithromycin in Dentistry: From Systemic Antibiotic to a Candidate for Local Therapeutic Delivery.Pharmaceutics · 2026Review
- Pharmacological strategies for targeting biofilms in otorhinolaryngologic infections and overcoming antimicrobial resistance (Review).Biomedical reports · 2025Review
- Antibiotic-ResistantMicroorganisms · 2025Review
- In Vitro and In Vivo Antibacterial and Antibiofilm Activity of Zinc Sulfate (ZnSOAntibiotics (Basel, Switzerland) · 2025Article
- A biocompatible β-cyclodextrin inclusion complex containing natural extracts: a promising antibiofilm agent.Nanoscale advances · 2025Article
- The effect of cCMP and cUMP on growth ofFrontiers in microbiology · 2025Article
- Combatting biofilm-mediated infections in clinical settings by targeting quorum sensing.Cell surface (Amsterdam, Netherlands) · 2024Review
- An insight on the powerful of bacterial quorum sensing inhibition.European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology · 2024Review
- Macrolide resistance through uL4 and uL22 ribosomal mutations in Pseudomonas aeruginosa.Nature communications · 2024Article
- Practical Guidance for Clinical Microbiology Laboratories: Updated guidance for processing respiratory tract samples from people with cystic fibrosis.Clinical microbiology reviews · 2024Review
- Biofilm Production and Its Implications in Pediatrics.Microorganisms · 2024Review
- Sterically hindered phenolic derivatives: effect on the production of Pseudomonas aeruginosa virulence factors, high-throughput virtual screening and ADME properties prediction.Archives of microbiology · 2024Article
- A gene network-driven approach to infer novel pathogenicity-associated genes: application tomSystems · 2023Article
- Selected strategies to fight pathogenic bacteria.Journal of enzyme inhibition and medicinal chemistry · 2023Review
- Biofilms as Battlefield Armor for Bacteria against Antibiotics: Challenges and Combating Strategies.Microorganisms · 2023Review
- Structure-Activity Relationships of Low Molecular Weight Alginate Oligosaccharide Therapy againstBiomolecules · 2023Article
- Spiramycin DisarmsAntibiotics (Basel, Switzerland) · 2023Article
- Antimicrobial Treatment ofAntibiotics (Basel, Switzerland) · 2022Review
56 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The consequences of O-acetylated alginate-producing Pseudomonas aeruginosa biofilms in the lungs of chronically infected cystic fibrosis (CF) patients are tolerance to both antibiotic treatments and effects on the innate and the adaptive defense mechanisms. In clinical trials, azithromycin (AZM) has been shown to improve the lung function of CF patients. The present study was conducted in accordance with previous in vitro studies suggesting that the effect of AZM may be the inhibition of alginate production, blockage of quorum sensing (QS), and increased sensitivity to hydrogen peroxide and the complement system. Moreover, we show that AZM may affect the polymerization of P. aeruginosa alginate by the incomplete precipitation of polymerized alginate and high levels of readily dialyzable uronic acids. In addition, we find that mucoid bacteria in the stationary growth phase became sensitive to AZM, whereas cells in the exponential phase did not. Interestingly, AZM-treated P. aeruginosa lasI mutants appeared to be particularly resistant to serum, whereas bacteria with a functional QS system did not. We show in a CF mouse model of chronic P. aeruginosa lung infection that AZM treatment results in the suppression of QS-regulated virulence factors, significantly improves the clearance of P. aeruginosa alginate biofilms, and reduces the severity of the lung pathology compared to that in control mice. We conclude that AZM attenuates the virulence of P. aeruginosa, impairs its ability to form fully polymerized alginate biofilms, and increases its sensitivity to complement and stationary-phase killing, which may explain the clinical efficacy of AZM.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.